Welcome to our dedicated page for Lantheus Holding SEC filings (Ticker: LNTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lantheus Holdings, Inc. (NASDAQ: LNTH) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including Forms 10-K, 10-Q and 8-K. These documents offer detailed information about Lantheus’ radiopharmaceutical-focused business, financial performance, risk factors, leadership changes and material transactions.
In its Form 8-K filings, Lantheus has reported key corporate events such as quarterly and year-to-date financial results, authorization of a stock repurchase program, acquisitions of Evergreen Theragnostics and Life Molecular Imaging, and the divestiture of its SPECT business. Filings also document leadership transitions, including the planned retirement of the Chief Executive Officer, the appointment of an Executive Chairperson and interim CEO, and changes in other senior roles. These disclosures help investors understand governance and compensation arrangements, including consulting and retirement agreements.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (accessible via the SEC’s EDGAR system and summarized on this page) typically contain segment information, discussion of products such as PYLARIFY, DEFINITY and Neuraceq, and descriptions of the company’s precision diagnostics, radiopharmaceutical oncology and strategic partnership activities. They also include extensive risk factor sections that discuss competitive dynamics, manufacturing and supply risks, regulatory considerations for PET imaging agents, and integration risks associated with acquisitions.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points, such as changes in outlook, major transactions, or updates on radiopharmaceutical pipeline assets like LNTH-2501 and MK-6240. Users can quickly see high-level insights from lengthy 10-K and 10-Q reports, as well as interpret 8-K items related to leadership changes or capital allocation. The filings page also surfaces insider and executive-related information reported in Forms 3, 4 and 5, allowing investors to monitor equity awards, vesting terms and other compensation-related details disclosed for Lantheus executives and directors.
Lantheus Holdings, Inc. (LNTH) reported that certain investment funds affiliated with Farallon (the "Farallon Funds") hold 6,883,227 shares of common stock, held indirectly. The filing notes the company had 67,994,149 shares outstanding as of August 1, 2025, and because the total shares outstanding were reduced, the Farallon Funds now beneficially own more than 10.0% of the common stock without any reported purchase by the reporting persons.
The Form 3 lists multiple Farallon-affiliated reporting persons who may be deemed to have investment discretion or indirect beneficial ownership through Farallon General Partners and Managing Members, while those parties disclaim beneficial ownership except to the extent of any pecuniary interest. The filing is limited to non-derivative holdings and includes an Exhibit 24 power of attorney.
Farallon Partners and affiliated managing members filed a Form 3 disclosing beneficial ownership of 6,883,227 shares of Lantheus Holdings, Inc. (ticker: LNTH). The filing, triggered by an event dated 08/06/2025, states that as of 08/01/2025 there were 67,994,149 shares outstanding and that, solely because the issuer reduced its outstanding share count, the Farallon Funds now hold in excess of 10.0% of common stock. The Form 3 emphasizes that this report does not reflect any acquisition by the reporting persons and that ownership is held indirectly by Farallon-managed funds with various managing members disclaiming direct beneficial ownership except to the extent of any pecuniary interest.
Paul Blanchfield, President and Director of Lantheus Holdings, Inc. (LNTH), reported an insider sale. On 08/13/2025 he disposed of 3,060 shares of common stock at $53.57 per share, leaving him with 108,214 shares beneficially owned. The filing notes the sale was executed under a Rule 10b5-1 trading plan adopted by the reporting person on 02/27/2025. The Form 4 was signed by an attorney-in-fact on 08/15/2025.
Janus Henderson Group plc filed an amended Schedule 13G reporting beneficial ownership in Lantheus Holdings, Inc. The filing lists an aggregate 6,938,984 shares, representing 10.0% of the class, with no sole voting or dispositive power and 6,938,984 shares held with shared voting and dispositive power.
The filing also identifies an indirect subsidiary, JHIUS, as potentially beneficially owning 6,242,218 shares (9.0%). The report includes issuer and filer addresses, a power of attorney executed Dec 9, 2022, and is signed by Kristin Mariani as Head of North America Compliance on 08/14/2025.
Form 144 filed for Lantheus Holdings, Inc (LNTH) discloses an intended sale of 3,060 common shares through Fidelity Brokerage with an aggregate market value of $163,924.20. The filing lists the approximate sale date as 08/13/2025 and identifies the securities exchange as NASDAQ. The shares to be sold were acquired through company programs: 221 shares via an ESPP purchase on 03/13/2023 (paid in cash) and 2,839 shares from restricted stock vesting on 03/02/2024, 03/03/2024, and 04/17/2024 as compensation.
The filing also reports a prior sale by Paul Blanchfield of 6,599 common shares on 06/05/2025 for gross proceeds of $525,610.35. Certain filer identification fields appear blank in the provided content. The document includes the standard seller representation that they have no undisclosed material adverse information.
Lantheus Holdings, Inc. reported that its Chief Commercial Officer, Amanda Morgan, has informed the company that she is taking leave from the company for personal reasons, effective August 8, 2025. The filing does not indicate any change to her title or name a replacement in this excerpt, only that she will be on leave. The update is presented as a leadership availability change rather than a broader strategic or financial event.
Lantheus (LNTH) Q2-25 10-Q highlights:
- Revenue slipped 4% YoY to $378.0 M as PYLARIFY sales moderated (-8%) and TechneLite continued to decline ahead of the planned SPECT divestiture. Six-month revenue down 2% to $750.8 M.
- Gross margin held at 64% (241.0/378.0). Opex flat YoY; R&D down 25% as AZEDRA spend ended. Operating income fell 14% to $88.0 M, but lower unrealised equity losses and higher interest income lifted net income 27% to $78.8 M (dil. EPS $1.12).
- Six-month net income dropped 22% to $151.7 M as Q1 faced a sharp mark-to-market equity loss.
- Cash flow from ops was a solid $194.7 M, offset by $296.2 M investing cash outflow, chiefly the $269 M acquisition of radiotherapeutics CDMO Evergreen Theragnostics. Cash & equivalents fell to $695.6 M; net cash still ~>$120 M versus $575 M 2.625% converts.
- Balance sheet adds $116.2 M Evergreen goodwill and $215 M IPR&D; fair-valued contingent consideration booked at $43.0 M.
- SPECT business classified as held-for-sale (assets $73.4 M, liabilities $29.8 M) under agreement with SHINE; no impairment recorded.
- Shareholder returns: repurchased 1.3 M shares for $100 M in Q2; $200 M total under $250 M 2024 program. 68.0 M basic shares outstanding (-2% YoY).
- Leverage covenants remain comfortable (net leverage 0.6×); no borrowings under $750 M revolver.
Outlook: While topline softness persists near term, the Evergreen acquisition broadens manufacturing capacity and adds Octevy & CDMO revenue options; SPECT sale will further concentrate on high-growth PET oncology and diagnostics franchise.
Lantheus Holdings (LNTH) Form 8-K highlights: On 21-Jul-25 the company’s UK subsidiary closed the previously announced acquisition of Life Molecular Imaging Ltd. for an upfront cash payment of $350 million, securing 100 % of the target’s share capital in line with the January 2025 Sale & Purchase Agreement.
Item 7.01 discloses that a 22-Jul-25 press release (Exhibit 99.1) announced the closing and the appointment of Dr. Ludger Dinkelborg as Head of Research & Development, effective 1-Aug-25. He will oversee Clinical Development, Regulatory Affairs, Clinical Operations, Program Management and AI/Biomarkers Solutions, reporting to the CEO.
No financial statements or pro-forma figures accompany the filing; the report focuses solely on completion of the asset acquisition and the senior leadership change.